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Abstract The rostrocaudal gradient (RCG) of markers
present in cerebrospinal fluid (CSF) has not been studied
adequately due to lack of appropriate control populations
and ethical restrictions. The aim of this study is to under-
stand the rostrocaudal gradient of CSF biomarkers. We
contacted a study comparing CSF levels of seven bio-
markers from cisternal (rostral) and lumbar (caudal) CSF
obtained from patients with trigeminal neuralgia and ten-
sion-type headache. The RCGs of CSF/serum albumin
ratio, 8-isoprostane. GFAP, total tau and beta amyloid
protein were higher than one. The RCGs of lactate, VEGF
and the heavy chain of neurofilament protein were lower
than one. The study provides new values for several
commonly examined markers of cisternal CSF. Knowledge
of the RCG gradient of different CSF markers is important
in interpreting studies reporting ventricular CSF values.
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Introduction
The dynamics of cerebrospinal fluid (CSF) markers along
the craniospinal axis has not been adequately studied due to
restricted access to ventricular CSF samples [1–3]. Many
brain-specific proteins are produced by the brain paren-
chyma and then are transported across the ependyma into
the CSF spaces. The large majority of them are derived
from serum, whereas others are produced exclusively by
the brain parenchyma. The movement of molecules across
the blood–brain barrier (BBB) and the blood-CSF barrier
depends on concentration gradients and flow [4]. The
particular dynamics of brain-derived proteins depend on
their sources which are either brain cells (neurons, glial
cells) or leptomeningeal cells [5]. From there, following
the bulk flow, a portion flows down the spinal axis to the
lumbar thecal sac where reabsorption as well as secretion
occurs.
Access to lumbar CSF provides us with diagnostic
information about different neurological conditions [6].
Levels of markers in CSF may be studied and conclusions
about the pathophysiological mechanisms underlying each
condition may be extrapolated [7]. However, the caudal
protein concentration from the lumbar thecal sac does not
accurately reflect the rostral concentrations from the cis-
ternal or ventricular CSF. Hence a combined knowledge of
both rostral and caudal concentration is needed for a
complete interpretation of the pathological significance of
each biomarker. Sampling of higher levels along the cra-
niospinal axis may not be ethically feasible hence limiting
the yield of diagnostic information from lumbar CSF only.
The aim of the study is to study the gradient of markers
along the craniospinal axis in a normal population. We also
provide cisternal values for markers who have not studied
previously in a normal population.
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Experimental Procedure
Cisternal CSF was collected from 6 patients suffering from
trigeminal neuralgia (TGN). All patients had idiopathic
TGN, other neurological causes having been excluded with
appropriate imaging. The patients have signed a consent
form to participate in the study. The study received ethical
approval from the Local Research Ethics Committee (Great
Ormond Street Hospital L.R.E.C.). Lumbar CSF was also
collected from 6 patients investigated for tension-type
headache and acted as a control group for lumbar samples
(LC). 5 mls of CSF was removed during lumbar puncture.
No pathology was found during routine investigations with
blood tests and imaging (MRI) for this group. The cisternal
CSF sample in patients with TGN was obtained following
durotomy during a microvascular decompression. All
patients were fasted at the time of sampling. Care was
taken to remove all blood by suction prior to opening the
dura, to ensure the sample was not contaminated. Red cell
and white cell counts were performed as per routine sample
analysis prior to centrifugation. All samples were centri-
fuged within 20 min following collection and the super-
natant aliquoted to 1 ml polypropelene tubes, frozen and
stored at -80C until analysis.
CSF albumin was measured using an in-house immu-
noturbidimetric assay; 5 ll of sample was mixed in an
ELISA plate well (Nunc) with 250 ll of anti-human
albumin (DiaSorin), diluted 1/16 in 0.9% saline, and
allowed to stand for ten minutes before being read at
350 nm. The assay was blanked with saline, calibrated on
a 0.5 g/l standard and calculated using the formula:
Albumin = ([OD test-OD blank)/(OD standard-OD
blank]) 9 1.0 g/l. Any samples above 0.5 g/l were diluted
in saline and re-assayed. CSF lactate was analyzed
enzymatically on an YSI 2700 STAT PLUS analyzer
(YSI, USA) according to manufacturer’s instructions.
VEGF was assayed using a commercial assay (Amersham
Biotrak
TM
human VEGF ELISA, GE Healthcare, U.K.).
8-isoprostane was calculated using a commercial kit
(8-Isoprostane EIA kit, Cayman Chemical Company, MI,
US). Heavy chain of the neurofilament protein (NfHSMI35)
was assayed by a technique described previously [8]. The
technique for the quantification of GFAP (GFAPSMI26)
has also been described previously [9]. Ab1-42 was mea-
sured using a commercial kit (Innotest b-amyloid (1–42),
Innogenetics, Belgium). The total tau was measured by
a commercial kit (Innotest hTAU Ag, Innogenetics,
Belgium). The markers chosen were studied as part of a
different published study in patients with idiopathic nor-
mal pressure hydrocephalus [10]. For NfH & GFAP
lumbar CSF levels reference values [11] from a larger
study with 33 samples were used. For total tau and Ab
1–42 lumbar CSF levels reference values [12] from a
larger study with 100 samples were used.
The median values and range of the examined markers
will be presented. The Mann–Whitney non-parametric test
was used to test for significant differences between the CC
and LC levels. Where reference values were used statistics
were not calculated.
The Spearman’s correlation test was used to test for
significant correlations between age, the Qalb and the other
markers both in cisternal and lumbar levels. The level of
significance was set at 0.05.
Results
The mean age of the 6 TGN patients was 56.5 (±9.3)
years (range: 52–76). The mean age of the 6 patients
investigated for headache was 50.5 (±10.6) years (range:
35–62). The difference in age of the two control groups
was not statistically significant (Mann–Whitney U test,
P = 0.234). The mean red cell count (RCC) in the cis-
ternal CSF prior to centrifugation was 2.66 (±3.88) and
the mean white cell count (WCC) 0.33 (±0/51). The
mean RCC in the lumbar CSF prior to centrifugation was
9.66 (±19.8), and the WCC 0.16 (±0.4). There were no
significant differences in the RCC and WCC of the cis-
ternal and lumbar CSF.
Differences Between Levels of Markers
No significant differences were found between the cisternal
and the lumbar levels of the examined markers.
Rostrocaudal Gradients of Markers
These are presented in Table 1. RCG higher than one
means that the concentration is higher in the cisternal CSF
when compared to the lumbar CSF. The RCG of GFAP
cannot be calculated since the median value is 0, however
it is assumed that it has to be higher than one since the
cisternal median is 0.2 pg/ml. The RCG of CSF/serum
albumin ratio, 8-isoprostane. GFAP and total tau and beta
amyloid protein was higher than one. The RCG of lactate,
VEGF and the heavy chain of neurofilament protein was
lower than one.
Correlation of Examined Markers with Qalb
All markers appear independent from Qalb, except the
cisternal levels of Ab1-42 which exhibit a significant posi-
tive correlation with Qalb (R = 0.886, P = 0.019).
Neurochem Res (2011) 36:528–532 529
123
Correlations Between Patient’s Age and Markers
Only VEGF levels demonstrated a positive trend with age
in patients with TGN (R = 0.771, P = 0.072). All other
markers did not show any correlation with age.
Discussion
The dynamics of brain-derived proteins have been
explained by Reiber [4, 5, 13, 14]. He suggested that the
CSF flow rate, and not the blood-CSF barrier dysfunction
as previously thought is the most important determinant for
understanding the pathological changes of both blood and
brain-derived proteins in CSF. In order to characterise the
dynamics he analysed the concentration gradients of CSF/
serum albumin ratio (Qalb) and the ventricular/lumbar CSF
concentration gradient. Pathologically decreased CSF flow
rate was characterised by increased CSF/serum albumin
ratio (Qalb). According to his theory therefore: (1) Brain-
derived proteins show a decrease in concentration between
ventricular and lumbar CSF (i.e. RCG [ 1) in normal
situations. Their concentration does not vary with patho-
logically decreasing CSF flow rate (i.e. in cases of a blood-
CSF barrier dysfunction) and therefore it is independent of
the Qalb. (2) In the case of CSF proteins from leptome-
ningeal cells an increasing concentration between normal
ventricular and lumbar CSF is observed (similar to blood-
derived proteins) (i.e. RCG \ 1). In the case of patholog-
ically decreasing CSF flow rate a linearly increasing
concentration in CSF is observed, that therefore being
dependent on Qalb. (3) Group with a non-negligible blood-
derived fractions in addition to brain-derived fractions. In
this group it is important to decide whether a quotient or
an absolute concentration of the brain-derived protein is
preferred as the most sensitive evaluation with reference to
the albumin quotient.
The age of patients does not appear to influence the
levels of markers; similar findings have been shown by
other studies using the same ELISA [8]. We found a
positive trend (but not a significant correlation) between
the age of patients with TGN and Ab 1–42 levels; similar
findings with normal groups have been reported [15, 16].
Other studies however have found a correlation of lactate
levels with age in opposition to our findings [17]. Due to
the inclusion of a narrow age range and the small number
of the subjects the current data cannot exclude correlations
of markers with age.
Under normal circumstances lactate clearance from CSF
is slowly taken up by the brain via diffusion [18] and by the
arachnoid villi by bulk flow [19] then partially metabolised
to pyruvate. The rostrocaudal gradient (RCG) of lactate
was 0.82. We verified the earlier studies of Posner and
Plum who found almost equal CSF lactate levels between
the cisterns and lumbar thecal sac, and that of Vamosi et al.
who, similarly to us, found higher lumbar lactate levels
when compared to cisternal levels [20, 21].
The RCG of 8-isoprostane was 1.06. It appears therefore
that 8-isoprostane is secreted and absorbed in an almost
equal rate across the craniospinal axis in control subjects.
The RCG for VEGF is 0.31. In the case of VEGF the
ventricular levels were independent of Qalb (Spearman’s
correlation, R = -0.32, P = 0.144). VEGF has both a
brain and blood-derived fraction. A limitation of our study
was that due to ethical restrictions we did not have access
to serum samples and therefore it is impossible to calculate
the blood-derived fraction of the ventricular VEGF levels.
GFAP is also a brain-derived protein. The RCG in
normal subjects cannot be calculated since the median
value for a control population is 0 (with a range of 0–60).
Table 1 Presentation of age, sex and the levels of the different markers examined
Cisternal control
CSF (n = 6)
Lumbar control
CSF (n = 6)
Statistical
significance
Rostrocau-dal
gradient
Correlation
with Qalb
Age (years) 56.5 (52–76) 50.5 (35–62) n.s
Sex (Male: Female) 4:2 2:4 N/A
Qalb 0.003 (0–2.41) 0.0017 (0.0002–0.0064) n.s 1.7 –
Lactate 1.71 (1.01–2.93) 2.07 (1.54–4.26) n.s 0.82 n.s
VEGF 6.27 (0–24.6) 20.19 (17.8–23.9) n.s 0.31 n.s
8-isoprostane 40.23 (38.12–45.06) 37.81 (36.28–43.07) n.s 1.06 n.s
GFAPSMI26 0.2 (0.13–1.31) 0 (0–60)a N/A – n.s
NfHSMI35 0.01 (0–1.34) 0.18 (0.07–0.30)a N/A 0.05 n.s
Total tau 285 (54.5–1158) 195 (121–294)b N/A 1.46 n.s
Ab1-42 930 (113–1458) 849(682–1063)
b N/A 1.09 R = 0.886 (0 = 0.019)
Spearman’s correlations are presented. Mann–Whitney test was used to test for statistical significance
The values presented are the median with the range in brackets. Reference values used from a [11] and b [12]
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Although one will assume that the gradient is[1 since the
cisternal median GFAP value is 0.2 pg/ml. The gradient
agrees with the model for brain-derived proteins described
by Reiber. The levels of NfH did not correlate with age in
any of the groups tested, agreeing with previous reports
[22]. The lumbar levels of NfH were almost 18 times
higher than the cisternal levels. According to Reiber’s
theory an active secretion of the protein should occur by
the leptomeninges along the craniospinal axis; such find-
ings have been demonstrated in cultured human cells in
vitro [23]. The levels appear independent of Qalb.
The cisternal levels of total tau were almost 1.5 times
higher in the control group when compared to the lumbar
levels. The levels were independent of Qalb consistent with
Reiber’s theory about the CSF dynamics of brain-derived
proteins. The RCG of Ab 1–42 is 1.09 in control subjects,
respectively. The Ab 1-42 levels are dependent on the Qalb
(R = 0.886, P = 0.019) in the control subjects. Increases
in Ab levels due to decreasing CSF clearance and hence
dependence in Qalb has been demonstrated in experimental
models of chronic hydrocephalus [24]. The dynamics of
Ab 1–42 suggest according to Reiber’s theory that Ab 1–42
is secreted by the leptomeningeal cells along the cranio-
spinal axis. It has been indeed shown that there is amyloid
accumulation in the cortical leptomeninges of both aged
individuals and patients with AD [25, 26]. The potential of
amyloid deposition in the spinal cord has been demon-
strated in vivo with MR imaging in cases of amyloidosis
and spinal vascular malformations [27, 28]. Authors of a
study where the fluctuation of Ab 1–42 levels were studied
assumed that there was no RCG in normal subjects [29].
However, they did not sample ventricular CSF but instead
collected 25–35 mls of lumbar CSF. Our study found a
small positive gradient (1.09). However, it has been shown
the volume of spinal CSF is a mean of 81 ± 13 ml in
normal individuals [30] rendering the above method of
calculating a RCG methodologically incorrect.
There are several limitations due to ethical restrictions.
We were therefore unable to measure the markers in serum
samples and hence calculate the blood-derived fraction of
some markers. Rostral and caudal values were also
obtained from different sets of subjects, however a lumbar
puncture in patients with TGN was not permitted for eth-
ical reasons, since the procedure is not part of the routine
diagnostic protocol. Although there may be an argument
against patients with TGN having non-pathological CSF
composition, there are no published studies in the literature
to reflect changes with regards to the markers studied. For
logistical reasons the samples were not obtained at the
same time of the day. Hence a bias may have been intro-
duced with regards to diurnal and seasonal rhythms, and
their effect on the levels of the markers. Effects that are
difficult to standardise such as the height of subjects may
effect the concentration of markers in lumbar CSF [31].
Intra-individual variations however may remain stable over
a short period [32]. Sampling cisternal CSF from patients
with TGN cannot exclude concomitant pathologies that
may affect the levels of the markers, however at the time of
surgery other pathologies were not known, and imaging of
the patients had excluded underlying pathologies. Last,
inter-laboratory variations in ELISA results reporting
cannot be excluded where reference values from larger
studies are used in the lumbar samples; however this is
balanced by the increased certainty of the reference values
the larger studies provide.
Conclusions
Due to the small clinical sample our data may not provide
reference values but may act as a starting point to provide a
further insight into the dynamics of several CSF markers in
a normal population, providing at the same time values of
cisternal CSF for several CSF markers never studied
before. Knowledge of the gradient of different CSF
markers is important in interpreting studies reporting ven-
tricular CSF values.
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